Comparing Nerlynx vs Tukysa
| Nerlynx (neratinib) | Tukysa (tucatinib) |
|
|---|
| Nerlynx (neratinib) | Tukysa (tucatinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Nerlynx (neratinib) is an oral kinase inhibitor that may be used alone for early-stage HER-2-positive breast cancer or in combination with capecitabine for advanced or metastatic HER2-positive... View more |
Prescription only
Prescribed for Breast Cancer, Colorectal Cancer. Tukysa may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Nerlynx (neratinib) | More about Tukysa (tucatinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Nerlynx has an average rating of 5.2 out of 10 from a total of 21 ratings on Drugs.com. 29% of reviewers reported a positive effect, while 33% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Nerlynx side effects |
View all Tukysa side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Nerlynx prices |
View all Tukysa prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
17 hours |
8.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 189 drugs are known to interact with Nerlynx:
|
A total of 507 drugs are known to interact with Tukysa:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
July 17, 2017 |
April 17, 2020 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Trazimera
Trazimera (trastuzumab-qyyp) is a biosimilar to Herceptin that may be used to treat certain types ...
Nolvadex
Nolvadex is used for breast cancer, breast cancer, adjuvant, breast cancer, male, breast cancer ...
Ogivri
Ogivri is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal ...
Ontruzant
Ontruzant is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal ...
Kanjinti
Kanjinti is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.